Secondary prevention: Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension

M. Lombardo, C. Alli, M. Broccolino, S. Ferrai, L. Montemurro, G. Zaini, D. Zanni

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To compare the effects of chronic antihypertensive treatment on left and right ventricular structure and function, 24 patients with mild to moderate, never-treated hypertension were randomized to receive fosinopril (20 mg daily) or amlodipine (10 mg daily) for 12 months. At baseline and subsequently at the end of third, sixth, and twelfth months, each patient underwent an integrated echocardiographic study and noninvasive ambulatory blood pressure monitoring. Both drugs significantly reduced blood pressure, casual or monitored (p <0.01), and left ventricular mass index (from 125 ± 32 to 100 ± 12 gm/m2 [p <0.02] with amlodipine and from 106 ± 18 to 89 ± 10 gm/m2 [p <0.02] with fosinopril). The decrease in left ventricular mass was essentially caused by a reduction of ventricular thickness. Free right ventricular wall thickness was also lowered in both groups, more consistently with amlodipine (from 8.0 ± 2.1 to 6.4 ± 0.8 mm; p <0.01), without an increase in plasma natriuretic peptide and insulin concentrations or heart rate. With both treatments, the decrease in ventricular mass was not associated with impairment of systolic function, whereas a trend toward an improvement of Doppler echocardiographic indexes of biventricular diastolic function was observed. In conclusion, both amlodipine and fosinopril induced similar qualitative effects on anatomy and function of both ventricles. The clinical meaning of these observations must be defined further by means of adequately sized prospective trials.

Original languageEnglish
Pages (from-to)557-564
Number of pages8
JournalAmerican Heart Journal
Volume134
Issue number3
DOIs
Publication statusPublished - 1997

Fingerprint

Amlodipine
Fosinopril
Secondary Prevention
Angiotensin-Converting Enzyme Inhibitors
Heart Ventricles
Calcium
Right Ventricular Function
Natriuretic Peptides
Ambulatory Blood Pressure Monitoring
Antihypertensive Agents
Anatomy
Heart Rate
Insulin
Blood Pressure
Hypertension
Essential Hypertension
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Secondary prevention : Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension. / Lombardo, M.; Alli, C.; Broccolino, M.; Ferrai, S.; Montemurro, L.; Zaini, G.; Zanni, D.

In: American Heart Journal, Vol. 134, No. 3, 1997, p. 557-564.

Research output: Contribution to journalArticle

@article{f6487cfc7a0f4b61b332bd85ea10a10f,
title = "Secondary prevention: Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension",
abstract = "To compare the effects of chronic antihypertensive treatment on left and right ventricular structure and function, 24 patients with mild to moderate, never-treated hypertension were randomized to receive fosinopril (20 mg daily) or amlodipine (10 mg daily) for 12 months. At baseline and subsequently at the end of third, sixth, and twelfth months, each patient underwent an integrated echocardiographic study and noninvasive ambulatory blood pressure monitoring. Both drugs significantly reduced blood pressure, casual or monitored (p <0.01), and left ventricular mass index (from 125 ± 32 to 100 ± 12 gm/m2 [p <0.02] with amlodipine and from 106 ± 18 to 89 ± 10 gm/m2 [p <0.02] with fosinopril). The decrease in left ventricular mass was essentially caused by a reduction of ventricular thickness. Free right ventricular wall thickness was also lowered in both groups, more consistently with amlodipine (from 8.0 ± 2.1 to 6.4 ± 0.8 mm; p <0.01), without an increase in plasma natriuretic peptide and insulin concentrations or heart rate. With both treatments, the decrease in ventricular mass was not associated with impairment of systolic function, whereas a trend toward an improvement of Doppler echocardiographic indexes of biventricular diastolic function was observed. In conclusion, both amlodipine and fosinopril induced similar qualitative effects on anatomy and function of both ventricles. The clinical meaning of these observations must be defined further by means of adequately sized prospective trials.",
author = "M. Lombardo and C. Alli and M. Broccolino and S. Ferrai and L. Montemurro and G. Zaini and D. Zanni",
year = "1997",
doi = "10.1016/S0002-8703(97)70095-4",
language = "English",
volume = "134",
pages = "557--564",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Secondary prevention

T2 - Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension

AU - Lombardo, M.

AU - Alli, C.

AU - Broccolino, M.

AU - Ferrai, S.

AU - Montemurro, L.

AU - Zaini, G.

AU - Zanni, D.

PY - 1997

Y1 - 1997

N2 - To compare the effects of chronic antihypertensive treatment on left and right ventricular structure and function, 24 patients with mild to moderate, never-treated hypertension were randomized to receive fosinopril (20 mg daily) or amlodipine (10 mg daily) for 12 months. At baseline and subsequently at the end of third, sixth, and twelfth months, each patient underwent an integrated echocardiographic study and noninvasive ambulatory blood pressure monitoring. Both drugs significantly reduced blood pressure, casual or monitored (p <0.01), and left ventricular mass index (from 125 ± 32 to 100 ± 12 gm/m2 [p <0.02] with amlodipine and from 106 ± 18 to 89 ± 10 gm/m2 [p <0.02] with fosinopril). The decrease in left ventricular mass was essentially caused by a reduction of ventricular thickness. Free right ventricular wall thickness was also lowered in both groups, more consistently with amlodipine (from 8.0 ± 2.1 to 6.4 ± 0.8 mm; p <0.01), without an increase in plasma natriuretic peptide and insulin concentrations or heart rate. With both treatments, the decrease in ventricular mass was not associated with impairment of systolic function, whereas a trend toward an improvement of Doppler echocardiographic indexes of biventricular diastolic function was observed. In conclusion, both amlodipine and fosinopril induced similar qualitative effects on anatomy and function of both ventricles. The clinical meaning of these observations must be defined further by means of adequately sized prospective trials.

AB - To compare the effects of chronic antihypertensive treatment on left and right ventricular structure and function, 24 patients with mild to moderate, never-treated hypertension were randomized to receive fosinopril (20 mg daily) or amlodipine (10 mg daily) for 12 months. At baseline and subsequently at the end of third, sixth, and twelfth months, each patient underwent an integrated echocardiographic study and noninvasive ambulatory blood pressure monitoring. Both drugs significantly reduced blood pressure, casual or monitored (p <0.01), and left ventricular mass index (from 125 ± 32 to 100 ± 12 gm/m2 [p <0.02] with amlodipine and from 106 ± 18 to 89 ± 10 gm/m2 [p <0.02] with fosinopril). The decrease in left ventricular mass was essentially caused by a reduction of ventricular thickness. Free right ventricular wall thickness was also lowered in both groups, more consistently with amlodipine (from 8.0 ± 2.1 to 6.4 ± 0.8 mm; p <0.01), without an increase in plasma natriuretic peptide and insulin concentrations or heart rate. With both treatments, the decrease in ventricular mass was not associated with impairment of systolic function, whereas a trend toward an improvement of Doppler echocardiographic indexes of biventricular diastolic function was observed. In conclusion, both amlodipine and fosinopril induced similar qualitative effects on anatomy and function of both ventricles. The clinical meaning of these observations must be defined further by means of adequately sized prospective trials.

UR - http://www.scopus.com/inward/record.url?scp=0031228267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031228267&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(97)70095-4

DO - 10.1016/S0002-8703(97)70095-4

M3 - Article

C2 - 9327716

AN - SCOPUS:0031228267

VL - 134

SP - 557

EP - 564

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -